ERBB2 and malignant colon neoplasm: However, addition of lapatinib to chemotherapy did produce a significant overall survival benefit in Asian patients in the Lapatinib Optimization Study in HER2-Positive Gastric Cancer (LOGiC) study.32 In addition, a patient with refractory colon cancer with ERBB2 CNA achieved SD as best response (Table 4).